<DOC>
	<DOC>NCT00760617</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals' influenza vaccine GSK2186877A in adults 65 year of age and older. This protocol posting deals with objectives &amp; outcome measures of the extension phase at year 1. The objectives &amp; outcome measures of the primary phase are presented in a separate protocol posting (NCT number = 00540592).</brief_summary>
	<brief_title>Evaluation of Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Years and Older</brief_title>
	<detailed_description />
	<mesh_term>Influenza, Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects who the investigator believes that they can and will comply with the requirements of the protocol. A male or female aged 1841 years or â‰¥65 years at the time of the vaccination and who participated in the 110847 study and completed the 6 month followup. Written informed consent obtained from the subject. Fee of acute aggravation of the health status as established by clinical evaluation (medical history and medical history directed examination) before entering into the study. Female subjects must be of nonchildbearing potential. Use of any investigational or nonregistered product (drug or vaccine) other than the study vaccine(s) within 30 days prior to vaccination, or planned use during the study period. Administration of other licensed vaccines within 2 weeks (for inactivated vaccines) or 4 weeks (for live vaccines) prior to enrolment in this study. Planned administration of an influenza vaccine other than the study vaccines or of a vaccine not foreseen in the study protocol during the entire study period. Vaccination against influenza since January 2008 with a seasonal influenza vaccine. Chronic administration (defined as more than 14 days) of immunosuppressants or other immunemodifying drugs within six months prior to the administration of the study vaccine. Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination. History of hypersensivity to a previous dose of influenza vaccine. History of allergy or reactions likely to be exacerbated by any component of the vaccine(s). Acute (active) clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by clinical evaluation (medical history and medical history directed physical examination) or preexisting laboratory screening tests. Acute disease at the time of enrolment. Administration of immunoglobulins and/or any blood products within the three months preceding the first administration of the study vaccine or planned administration during the study. Any medical conditions in which IM injections are contraindicated. Lactating female, female planning to become pregnant or planning to discontinue contraceptive precautions.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Elderly</keyword>
</DOC>